Skip to main content
. 2017 Aug 23;8(14):2809–2815. doi: 10.7150/jca.18286

Figure 3.

Figure 3

Progression-free survival (PFS) to cetuximab-containing chemotherapy in patients with wild-type KRAS, according to the status of microsatellite instability (A), and location of the primary tumor (B).